Quetiapine (Seroquel)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Schizophrenia, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (97)
Bipolar Disorder
NCT01737268 · Astellas Pharma Inc
2012-10-29 – 2016-06-29 · Bipolar Disorder, Elderly
What this study did
NCT02362412 · Astellas Pharma Inc
2015-02-18 – 2016-02-06 · Bipolar Depression
What this study did
NCT01197846 · Centro de Investigación Biomédica en Red de Salud Mental
2010-09 – 2012-07 · Bipolar Disorder
What this study did
NCT00879307 · Hospital de Clinicas de Porto Alegre
2009-03 – 2011-09 · BIPOLAR DISORDER
What this study did
NCT00671853 · University Hospitals Cleveland Medical Center
2008-04 – 2011-03 · Bipolar Disorder, Anxiety, Anxiety Disorders, Substance Use Disorders
What this study did
NCT00857584 · AstraZeneca
Run by former owner AstraZeneca
2009-05 – 2011-02 · Bipolar Disorder, Bipolar Depression
What this study did
NCT00183443 · Palo Alto Veterans Institute for Research
2005-02 – 2010-11 · Bipolar Disorder, Schizophrenia
What this study did
NCT00252226 · Mood Disorders Center of Ottawa
2004-06 – 2007-12 · Bipolar Disorder
What this study did
NCT00277667 · Lindner Center of HOPE
2004-02 – 2007-12 · Bipolar Disorder
What this study did
NCT00227305 · AstraZeneca
Run by former owner AstraZeneca
2004-08 – 2007-12 · Schizophrenia, Bipolar I Disorder
What this study did
NCT00232414 · University of Cincinnati
2005-10 – 2007-12 · Bipolar I Disorder
What this study did
NCT00486798 · AstraZeneca
Run by former owner AstraZeneca
2007-05 – 2007-08 · Psychotic Disorders, Schizophrenia, Bipolar Disorder
What this study did
NCT00314184 · AstraZeneca
Run by former owner AstraZeneca
2005-03 – 2007-07 · Bipolar Disorder
What this study did
NCT00206141 · AstraZeneca
Run by former owner AstraZeneca
2005-08 – 2007-05 · Bipolar Disorder, Bipolar Depression, Depression
What this study did
NCT00119652 · AstraZeneca
Run by former owner AstraZeneca
2005-05 – 2007-05 · Bipolar Disorder, Bipolar Depression, Depression
What this study did
NCT00114686 · AstraZeneca
Run by former owner AstraZeneca
2006-01 – 2007-04 · Bipolar I Disorder, Alcohol Dependence
What this study did
NCT00090311 · AstraZeneca
Run by former owner AstraZeneca
2004-07 – 2006-07 · Bipolar Disorder
What this study did
NCT00448578 · AstraZeneca
Run by former owner AstraZeneca
2005-08 – 2006-06 · Mania, Bipolar Disorder
What this study did
NCT00254774 · AstraZeneca
Run by former owner AstraZeneca
2002-01 – 2006-03 · Bipolar Disorder
What this study did
NCT00097032 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-10 – 2005-05 · Bipolar Disorder
What this study did
NCT00060489 · AstraZeneca
Run by former owner AstraZeneca
2002-09 – 2003-09 · Bipolar Disorder, Depression, Bipolar
What this study did
Schizophrenia
NCT05603104 · Dr. Inge Winter
2025-04-27 – 2026-06-24 · Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT01810380 · H. Lundbeck A/S
2013-03 – 2014-12 · Schizophrenia
What this study did
NCT01672554 · Corporation de Recherche en Neuropsycho Pharmacologie de Quebec
2008-12 – 2013-10 · Schizophrenia, Anxiety
What this study did
NCT02142556 · Tri-Service General Hospital (TSGH)
2008-11 – 2012-03 · Schizophrenia
What this study did
NCT01071135 · Hannover Medical School
2009-09 – 2010-08 · Schizophrenia
What this study did
NCT00882518 · AstraZeneca
Run by former owner AstraZeneca
2009-04 – 2010-07 · Schizophrenia
What this study did
NCT00640601 · AstraZeneca
Run by former owner AstraZeneca
2008-03 – 2010-07 · Schizophrenia
What this study did
NCT00852631 · AstraZeneca
Run by former owner AstraZeneca
2009-02 – 2010-05 · Schizophrenia
What this study did
NCT00640562 · AstraZeneca
Run by former owner AstraZeneca
2008-02 – 2010-02 · Schizophrenia, Depression
What this study did
NCT00347425 · Solvay Pharmaceuticals
2006-12 – 2008-02 · Schizophrenia and Schizoaffective Disorder
What this study did
NCT00334126 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-04 – 2007-09 · Schizophrenia
What this study did
NCT00457899 · AstraZeneca
Run by former owner AstraZeneca
2007-07 – 2007-09 · Schizophrenia, Schizoaffective Disorders, Psychotic Disorders
What this study did
NCT00090324 · AstraZeneca
Run by former owner AstraZeneca
2004-09 – 2007-06 · Schizophrenia
What this study did
NCT00234377 · AstraZeneca
Run by former owner AstraZeneca
2004-11 – 2006-05 · Schizophrenia
What this study did
NCT00228462 · AstraZeneca
Run by former owner AstraZeneca
2005-03 – 2006-04 · Schizophrenia
What this study did
NCT00304473 · AstraZeneca
Run by former owner AstraZeneca
2004-08 – 2006-04 · Schizophrenia
What this study did
NCT00206128 · AstraZeneca
Run by former owner AstraZeneca
2004-11 – 2006-02 · Schizophrenia
What this study did
NCT00206115 · AstraZeneca
Run by former owner AstraZeneca
2004-11 – 2005-12 · Schizophrenic Disorder
What this study did
NCT00328978 · AstraZeneca
Run by former owner AstraZeneca
2003-10 – 2005-09 · Schizophrenia, Schizoaffective Disorders
What this study did
NCT00085891 · AstraZeneca
Run by former owner AstraZeneca
2004-06 – 2005-09 · Schizophrenia
What this study did
NCT00161018 · University of Maryland, Baltimore
2003-11 – 2004-11 · Schizophrenia
What this study did
Other / comorbidity
NCT07760168 · All India Institute of Medical Sciences, Bhubaneswar
2026-08-30 – 2028-08-30 · Treatment Resistant Depression (TRD)
What this study did
NCT06333990 · Foundation for Advancing Veterans' Health Research
2024-07-09 – 2028-06 · Mild Traumatic Brain Injury
What this study did
Phase 2/3 (7)
Bipolar Disorder
NCT01725308 · Astellas Pharma Inc
2012-02-07 – 2016-07-11 · Bipolar Disorder
What this study did
NCT00411463 · University of Pittsburgh
2006-12 – 2010-09 · Bipolar II Disorder
What this study did
Schizophrenia
NCT00297947 · Manhattan Psychiatric Center
2004-12 – 2014-10 · Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT06062953 · Lone Baandrup
2023-09-18 – 2029-02-28 · Psychiatric Disorders, Insomnia
What this study did
NCT03572257 · Medical College of Wisconsin
2019-04-15 – 2020-03-02 · Delirium
What this study did
NCT00462618 · Michael E. DeBakey VA Medical Center
2007-04 – 2008-03 · Insomnia
What this study did
NCT00215254 · Duke University
2004-03 – 2006-02 · Social Anxiety Disorder
What this study did
Phase 2 (21)
Bipolar Disorder
NCT00622245 · H. Lundbeck A/S
2008-01 – 2009-11 · Depression in Patients With Bipolar Disorder
What this study did
Schizophrenia
NCT07152184 · University Hospital, Strasbourg, France
2026-10-01 – 2032-02-01 · Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
What this study did
NCT02462473 · Janssen Research & Development, LLC
2015-05 – 2016-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00254787 · AstraZeneca
Run by former owner AstraZeneca
2005-06 – 2006-01 · Schizophrenia
What this study did
Other / comorbidity
NCT05793632 · Ain Shams University
2023-03-01 – 2023-04-15 · Delirium
What this study did
NCT05303935 · Flinders University
2022-05-25 – 2023-04-04 · Sleep Apnea, Obstructive
What this study did
NCT01697709 · New York State Psychiatric Institute
2012-10-01 – 2017-04-30 · Cannabis Dependence
What this study did
NCT01189318 · Ewha Womans University
2012-03 – 2014-02 · Major Depressive Disorder
What this study did
NCT00674765 · University of Pennsylvania
2008-01 – 2014-01 · Alcoholism
What this study did
NCT01725282 · Astellas Pharma Inc
2011-12-14 – 2013-08-24 · Major Depressive Disorder
What this study did
NCT00872716 · University Hospital Muenster
2009-04 – 2011-03 · Specific Phobia
What this study did
NCT00954681 · New York State Psychiatric Institute
2009-08 – 2010-08 · Cannabis Dependence
What this study did
NCT00498628 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2007-12 – 2010-03 · Alcoholism, Alcohol Abuse
What this study did
NCT00561587 · Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
2007-11 – 2010-02 · Alcohol Relapse Prevention, Alcoholism, Alcohol Drinking, Alcohol Consumption, Alcohol Abuse
What this study did
NCT00584688 · University of South Florida
2007-02 – 2009-08 · Anorexia Nervosa
What this study did
NCT00743366 · New York State Psychiatric Institute
2008-08 – 2009-03 · Marijuana Smoking
What this study did
NCT00681668 · AstraZeneca
Run by former owner AstraZeneca
2007-08 – 2008-10 · Postpartum Depressive Disorder
What this study did
NCT00733668 · AstraZeneca
Run by former owner AstraZeneca
2006-03 – 2007-11 · Major Depressive Disorder
What this study did
NCT00254748 · AstraZeneca
Run by former owner AstraZeneca
2004-06 – 2007-06 · Borderline Personality Disorder
What this study did
NCT00318539 · AstraZeneca
Run by former owner AstraZeneca
2003-12 – 2006-08 · Obsessive Compulsive Disorder
What this study did
NCT00550147 · Indiana University
2004-02 – 2005-11 · Attention Deficit Disorder With Hyperactivity
What this study did
Phase 1/2 (3)
Schizophrenia
NCT02650102 · Shanxi Medical University
2013-01 – 2016-12 · Schizophrenia
What this study did
Other / comorbidity
NCT02087631 · University of Calgary
2014-12 – 2019-07 · Multiple Sclerosis
What this study did
NCT02056171 · Weill Medical College of Cornell University
2015-03 – 2016-12 · Delirium
What this study did
Phase 1 (28)
Bipolar Disorder
NCT03872596 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2019-03-27 – 2019-11-27 · Bipolar Disorder, Schizophrenia
What this study did
NCT02087579 · Janssen Research & Development, LLC
2014-02 – 2014-12 · Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
What this study did
Schizophrenia
NCT02901587 · H. Lundbeck A/S
2016-09 – 2018-04-18 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT02051387 · Central Institute of Mental Health, Mannheim
2013-01 – 2017-08 · Schizophrenia
What this study did
NCT00919607 · AstraZeneca
Run by former owner AstraZeneca
2009-06 – 2010-03 · Schizophrenia
What this study did
Other / comorbidity
NCT06546358 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2024-09 – 2025-12 · Postpartum Depression
What this study did
NCT04950868 · Verinder Sharma
2022-03-18 – 2025-06-01 · Postpartum Depression
What this study did
NCT05240261 · Assiut University
2022-05-01 – 2024-12-31 · Chronic Kidney Diseases
What this study did
NCT04280965 · The University of Texas Health Science Center at San Antonio
2019-02-01 – 2022-10-17 · Post Traumatic Stress Disorder
What this study did
NCT05235230 · Future University in Egypt
2021-05-19 – 2021-06-03 · Bioequivalence
What this study did
NCT04310579 · Food and Drug Administration (FDA)
2020-06-15 – 2021-05-25 · Hypercapnia, Ventilatory Depression
What this study did
NCT00087750 · National Institute on Drug Abuse (NIDA)
started 2003-10 · Cocaine-Related Disorders
What this study did
NCT02131545 · Mayo Clinic
2014-06 – 2016-07 · Dementia, Delirium
What this study did
NCT01871701 · Seoul National University Hospital
2012-11 – 2014-05 · Healthy
What this study did
NCT00606541 · Duke University
2008-01 – 2012-11 · Social Anxiety Disorder
What this study did
NCT01607762 · Janssen Research & Development, LLC
2012-02 – 2012-10 · Healthy
What this study did
NCT01919008 · Astellas Pharma Inc
2012-03-26 – 2012-06-22 · Major Depressive Disorder
What this study did
NCT01400165 · University of Ottawa
2011-07 – 2011-12 · Healthy
What this study did
NCT01903200 · Astellas Pharma Inc
2010-02 – 2011-09 · Major Depressive Disorder Patients
What this study did
NCT01908296 · Astellas Pharma Inc
2011-07 – 2011-08 · Healthy, Pharmacokinetics of Quetiapine
What this study did
NCT01924520 · Astellas Pharma Inc
2010-11 – 2011-05 · Major Depressive Disorder
What this study did
NCT01566487 · Dr. Reddy's Laboratories Limited
2010-06 – 2010-06 · Healthy
What this study did
NCT01871974 · Astellas Pharma Inc
2009-05 – 2010-03 · Major Depressive Disorder Patients
What this study did
NCT00832221 · AstraZeneca
Run by former owner AstraZeneca
2009-01 – 2009-09 · Depression
What this study did
NCT00567866 · University of Arkansas
2008-01 – 2009-09 · Methamphetamine Dependence
What this study did
NCT01871987 · Astellas Pharma Inc
2009-06 – 2009-08 · Healthy, Plasma Concentration Change of Quetiapine
What this study did
NCT00702676 · AstraZeneca
Run by former owner AstraZeneca
2008-07 – 2008-08 · Healthy Volunteers
What this study did
NCT00255879 · University of California, San Diego
1999-01 – 2004-08 · Dyskinesia, Drug-Induced
What this study did
Phase 4 (112)
Bipolar Disorder
NCT06433635 · Massachusetts General Hospital
2024-10-01 – 2030-02-28 · Bipolar I Disorder, Depression
What this study did
NCT02845453 · Boston Medical Center
2017-01-20 – 2021-04-07 · Substance Use Disorders, Bipolar Disorder, Mood Disorders
What this study did
NCT01938859 · Shanghai Mental Health Center
2012-06 – 2018-12 · Bipolar Disorder
What this study did
NCT01588457 · The University of Texas Health Science Center at San Antonio
2011-06 – 2016-12 · Bipolar I Disorder, Bipolar II Disorder
What this study did
NCT01893229 · Guiyun Xu
2013-09 – 2015-12 · Bipolar Disorder
What this study did
NCT01133821 · Holly Swartz
2010-08 – 2015-10 · Bipolar Disorder, Depression
What this study did
NCT01526148 · University Hospitals Cleveland Medical Center
2012-01 – 2015-01 · Bipolar Disorder
What this study did
NCT00393978 · University of Cincinnati
2006-11 – 2014-03 · Bipolar Disorder, Cannabis-Related Disorder
What this study did
NCT01331304 · Massachusetts General Hospital
2010-09 – 2013-09 · Bipolar Disorder
What this study did
NCT00746421 · Emory University
2010-01 – 2012-04 · Bipolar Disorder, Cognitive Impairment
What this study did
NCT00186043 · Stanford University
2008-08 – 2011-08 · Bipolar II Disorder
What this study did
NCT00457197 · University of Texas Southwestern Medical Center
2007-03 – 2011-07 · Bipolar Disorder, Alcohol Dependence
What this study did
NCT01195363 · The University of Texas Health Science Center at San Antonio
2007-04 – 2011-06 · Bipolar Disorder
What this study did
NCT00579280 · University of South Florida
2007-07 – 2010-12 · Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
What this study did
NCT00550394 · University of Cincinnati
2008-04 – 2010-06 · Bipolar Disorder, Alcohol Abuse
What this study did
NCT00521365 · AstraZeneca
Run by former owner AstraZeneca
2008-05 – 2009-08 · Bipolar Disorder, Bipolar Affective Psychosis, Mania, Manic Disorder, Manic State
What this study did
NCT00672490 · AstraZeneca
Run by former owner AstraZeneca
2008-04 – 2009-07 · Acute Mania in Bipolar Disorder
What this study did
NCT00181883 · Massachusetts General Hospital
2005-02 – 2009-04 · Bipolar Disorder, Mania
What this study did
NCT00223210 · University of Texas Southwestern Medical Center
2005-11 – 2007-12 · Bipolar Disorder, Cocaine Dependence
What this study did
NCT00048802 · Northwell Health
2002-08 – 2006-08 · Bipolar Disorder
What this study did
NCT00139074 · AstraZeneca
Run by former owner AstraZeneca
2005-07 – 2006-06 · Bipolar Disorder
What this study did
NCT00223249 · University of Texas Southwestern Medical Center
2002-11 – 2004-08 · Bipolar Disorder, Alcohol Abuse/Dependence
What this study did
NCT00182013 · Massachusetts General Hospital
2001-06 – 2004-02 · Bipolar Spectrum Disorder
What this study did
Schizophrenia
NCT04446234 · Shanghai Mental Health Center
2021-05 – 2022-12-31 · Schizophrenia
What this study did
NCT03568500 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2018-05-21 – 2019-09-06 · Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
What this study did
NCT02307396 · Technical University of Munich
2015-02-01 – 2016-06-22 · Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders
What this study did
NCT02526030 · Fundación Marques de Valdecilla
2008-10 – 2015-06 · Schizophrenia, Psychotic Disorders
What this study did
NCT02305823 · Fundación Marques de Valdecilla
2005-10 – 2014-05 · Schizophrenia, Psychotic Disorders
What this study did
NCT01164059 · University of Bremen
2010-02 – 2014-03 · Schizophrenia
What this study did
NCT02534363 · Fundación Marques de Valdecilla
2005-10 – 2013-01 · Schizophrenia, Psychotic Disorders
What this study did
NCT01250847 · Severance Hospital
2010-11 – 2012-10 · Abnormal Mental State, Schizophrenia
What this study did
NCT01213836 · AstraZeneca
Run by former owner AstraZeneca
2010-11 – 2011-08 · Schizophrenia
What this study did
NCT00511277 · Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
2007-08 – 2011-04 · Schizophrenia
What this study did
NCT00554658 · University of Regensburg
2008-03 – 2011-03 · Schizophrenia
What this study did
NCT00986167 · Bayside Health
2009-10 – 2010-10 · Schizophrenia, Psychosis
What this study did
NCT01047215 · Taichung Veterans General Hospital
2009-08 – 2010-06 · Schizophrenia, Bipolar
What this study did
NCT00817648 · Shanghai Mental Health Center
2008-12 – 2010-05 · Schizophrenia
What this study did
NCT00954122 · AstraZeneca
Run by former owner AstraZeneca
2009-09 – 2010-04 · Schizophrenia
What this study did
NCT00779506 · AstraZeneca
Run by former owner AstraZeneca
2008-11 – 2009-07 · Schizophrenia
What this study did
NCT00797927 · National Taiwan University Hospital
2007-01 – 2009-04 · Schizophrenia
What this study did
NCT00044655 · Icahn School of Medicine at Mount Sinai
2001-07 – 2009-03 · Schizophrenia
What this study did
NCT00681629 · AstraZeneca
Run by former owner AstraZeneca
2008-07 – 2008-11 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
What this study did
NCT00206102 · AstraZeneca
Run by former owner AstraZeneca
2003-09 – 2008-10 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00156715 · Dartmouth-Hitchcock Medical Center
2004-03 – 2008-10 · Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
What this study did
NCT00498004 · Inje University
2007-08 – 2008-09 · Schizophrenia
What this study did
NCT00370500 · University of Erlangen-Nürnberg Medical School
2007-04 – 2008-07 · Schizophrenia
What this study did
NCT00255515 · AstraZeneca
Run by former owner AstraZeneca
2005-09 – 2007-12 · Schizophrenia
What this study did
NCT00304616 · Korea Otsuka Pharmaceutical Co., Ltd.
2004-10 – 2007-10 · Schizophrenia
What this study did
Early phase / not applicable (35)
Bipolar Disorder
NCT05480150 · First Affiliated Hospital of Zhejiang University
2021-11-01 – 2026-12-31 · Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic
What this study did
NCT05098353 · Federal Stare Budgetary Scientific Institution, Mental Health Research Center
2021-04-10 – 2021-12-01 · Bipolar Affective Disorder
What this study did
NCT02451306 · RWTH Aachen University
2015-06 – 2018-05 · Depression, Bipolar Disorder
What this study did
NCT00893581 · University of Cincinnati
2009-03 – 2016-03 · Mania, Bipolar Disorder
What this study did
NCT00742638 · Shanghai Jiao Tong University School of Medicine
2008-03 – 2010-08 · Bipolar Disorder
What this study did
NCT01527448 · BC Women's Hospital & Health Centre
2008-04 – 2010-07 · Postpartum Depression
What this study did
NCT01570959 · Roxane Laboratories
2007-04 – 2007-11 · Bipolar I Disorder
What this study did
NCT01570894 · Roxane Laboratories
2007-07 – 2007-07 · Bipolar I Disorder
What this study did
NCT01570907 · Roxane Laboratories
2007-06 – 2007-07 · Treatment for Bipolar I Disorder
What this study did
NCT00227123 · University of Texas Southwestern Medical Center
2002-10 – 2006-11 · Bipolar Disorder, Cocaine Dependence, Methamphetamine Dependence
What this study did
Schizophrenia
NCT00642369 · Guang Dong Provincial Mental Health Institute
2008-03 – 2009-10 · Schizophrenia
What this study did
NCT00493233 · Centre for Addiction and Mental Health
2006-11 – 2008-12 · Schizophrenia
What this study did
NCT00515723 · Washington University School of Medicine
2001-09 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
What this study did
NCT00207064 · Birte Glenthoj
2004-04 – 2008-09 · Schizophrenia
What this study did
NCT00222495 · University of Minnesota
2002-08 – 2006-08 · Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
What this study did
NCT00231101 · Arthur P. Noyes Research Foundation
2004-01 – 2006-06 · Smoking Behavior in Schizophrenia
What this study did
NCT00018642 · US Department of Veterans Affairs
1997-04 – 2002-03 · Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT04728581 · St. Anna Ziekenhuis, Geldrop, Netherlands
2024-01-01 – 2027-01-01 · Osteo Arthritis Knee, Insomnia
What this study did
NCT05801289 · Ain Shams University
2022-12-04 – 2023-04 · Delirium
What this study did
NCT04209166 · Shanghai Mental Health Center
2019-08-12 – 2022-10-31 · Major Depressive Disorder
What this study did
NCT06200584 · Dr Rabia Arshad
2021-01-01 – 2021-06-10 · Antipsychotics and Neuroleptics Toxicity
What this study did
NCT02467933 · Abdul Latif Jameel Poverty Action Lab
2015-04 – 2017-04 · Economics, Fraud, Delivery of Health Care, Health Expenditures, Centers for Medicare and Medicaid Services (U.S.)
What this study did
NCT01066156 · Cambridge Health Alliance
2010-02 – 2015-03 · Post-Traumatic Stress Disorder
What this study did
NCT02137616 · Central South University
2012-06 – 2014-12 · Psychotic Disorders
What this study did
NCT00688818 · Centre for Addiction and Mental Health
2008-06 – 2013-06 · Major Depressive Disorder, Dysthymic Disorder, Anxiety Disorders, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Post-traumatic Stress Disorder
What this study did
NCT01971203 · Icahn School of Medicine at Mount Sinai
2009-09 – 2013-06 · Major Depressive Disorder, Generalized Anxiety Disorder
What this study did
NCT00617396 · University of North Carolina, Chapel Hill
2008-02 – 2012-05 · Functional Bowel Disorders
What this study did
NCT00631748 · Seattle Institute for Biomedical and Clinical Research
2008-02 – 2010-07 · Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
What this study did
NCT00518973 · University of California, San Diego
2006-07 – 2010-05 · Anorexia Nervosa
What this study did
NCT00232570 · University of Vermont
2005-11 – 2010-01 · Alzheimer's Disease, Insomnia
What this study did
NCT00328822 · Khon Kaen University
2006-12 – 2007-08 · Primary Insomnia
What this study did
NCT00280501 · Medical University of Vienna
2005-08 – 2006-08 · Regional Blood Flow, Ocular Physiology
What this study did
NCT00015548 · National Institute of Mental Health (NIMH)
2001-03 – 2004-10 · Alzheimer's Disease
What this study did
Used as active comparator (39)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (15)
Bipolar Disorder
NCT00857818 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2009-04 – 2010-03 · Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
What this study did
NCT00309699 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-04 – 2007-11 · Bipolar Disorder, Mood Disorders
What this study did
Schizophrenia
NCT04115319 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2019-11-21 – 2022-12-30 · Schizophrenia
What this study did
NCT03465787 · Bukwang Pharmaceutical
2018-04-09 – 2022-10-26 · Schizophrenia
What this study did
NCT00789698 · Sumitomo Pharma America, Inc.
2008-12 – 2011-07 · Chronic Schizophrenia
What this study did
NCT00790192 · Sumitomo Pharma America, Inc.
2008-10 – 2010-07 · Schizophrenia
What this study did
NCT00654706 · H. Lundbeck A/S
2008-03 – 2010-03 · Schizophrenia, Cognition
What this study did
NCT00704509 · H. Lundbeck A/S
2008-06 – 2009-11 · Schizophrenia
What this study did
NCT00658645 · H. Lundbeck A/S
2008-03 – 2009-11 · Schizophrenia
What this study did
NCT00396214 · Solvay Pharmaceuticals
2007-04 – 2008-01 · Schizophrenia
What this study did
NCT00216476 · Janssen-Cilag International NV
2004-10 – 2007-11 · Schizophrenia, Psychotic Disorders
What this study did
Other / comorbidity
NCT00315900 · Tuscaloosa Research & Education Advancement Corporation
2006-05-01 – 2008-02-28 · Agitation, Dementia
What this study did
Phase 2/3 (1)
Schizophrenia
NCT01129674 · Denovo Biopharma LLC
2010-06 – 2012-10 · Schizophrenia
What this study did
Phase 2 (5)
Bipolar Disorder
NCT07654348 · First Affiliated Hospital of Zhejiang University
2026-07-01 – 2029-07-01 · Bipolar Disorder II
What this study did
NCT00771134 · H. Lundbeck A/S
2008-12 – 2009-08 · Bipolar Disorder
What this study did
Other / comorbidity
NCT04521478 · Boehringer Ingelheim
2020-11-20 – 2024-02-02 · Depressive Disorder, Major
What this study did
NCT04164758 · ACADIA Pharmaceuticals Inc.
2019-10-23 – 2020-09-25 · Parkinson's Disease
What this study did
Phase 1 (4)
Schizophrenia
NCT05542264 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-11-15 – 2024-02-12 · Schizophrenia
What this study did
NCT05402111 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-06-13 – 2023-09-27 · Schizophrenia
What this study did
Other / comorbidity
NCT01603173 · IPCA Laboratories Ltd.
2011-04 – 2011-11 · Fasting State
What this study did
NCT01603186 · IPCA Laboratories Ltd.
2011-04 – 2011-11 · Fed
What this study did
Phase 4 (12)
Bipolar Disorder
NCT02562287 · Hospital de Clinicas de Porto Alegre
2015-10 – 2020-12 · Bipolar Disorder
What this study did
NCT00397020 · University of California, San Diego
2006-12 – 2008-12 · Bipolar Disorder
What this study did
Schizophrenia
NCT02282085 · Matt Byerly
2014-12 – 2017-12 · Schizophrenia
What this study did
NCT01157351 · Janssen Scientific Affairs, LLC
2010-05 – 2013-12 · Schizophrenia
What this study did
NCT01193166 · Ortho-McNeil Janssen Scientific Affairs, LLC
2010-08 – 2012-09 · Schizophrenia
What this study did
NCT00330863 · Northwell Health
2006-05 – 2011-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00423878 · National Institute of Mental Health (NIMH)
2007-01 – 2010-03 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00508157 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2007-11-01 – 2009-03-01 · Metabolic Syndrome, Schizophrenia
What this study did
NCT00654576 · Central South University
2005-02 – 2007-12 · Schizophrenia
What this study did
Other / comorbidity
NCT05085808 · University of Southern California
2028-03-01 – 2030-12-01 · Delirium, Morality, Quality of Life, Psych, Treatment Side Effects
What this study did
NCT04936126 · All India Institute of Medical Sciences, Bhubaneswar
2021-08-07 – 2024-09-07 · Treatment Resistant Depression
What this study did
NCT00806234 · Johns Hopkins University
2009-01 – 2014-03 · Psychotic Disorders
What this study did
Early phase / not applicable (2)
Schizophrenia
NCT02192723 · Beijing HuiLongGuan Hospital
2012-06 – 2014-06 · Schizophrenia
What this study did
Other / comorbidity
NCT06581302 · Shanghai Jiao Tong University School of Medicine
2024-09-01 – 2025-12-30 · Psychotic Disorders
What this study did
Appears in other studies (10)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Schizophrenia
NCT00237913 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-07 – 2005-08 · Schizophrenia
What this study did
NCT00159770 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2001-11 – 2004-09 · Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
What this study did
Other / comorbidity
NCT01858948 · University of Cincinnati
2013-07 – 2018-04 · Bipolar Youth Treated With Second-generation Antipsychotics
What this study did
Phase 2 (4)
Schizophrenia
NCT03557931 · Astellas Pharma Global Development, Inc.
2018-07-13 – 2019-10-21 · Schizophrenia
What this study did
NCT00509067 · Georgetown University
2007-11 – 2011-03 · Schizophrenia
What this study did
Other / comorbidity
NCT00893841 · Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
2009-02 – 2013-01 · Bipolar Depression
What this study did
NCT01165541 · Dartmouth-Hitchcock Medical Center
2010-09 – 2012-10 · Alcohol Dependence
What this study did
Phase 4 (2)
Schizophrenia
NCT02040883 · Qingyun Yin
2014-02 – 2014-12 · Schizophrenia
What this study did
NCT00325689 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-07 – 2007-10 · Schizophrenia, Schizoaffective Disorder
What this study did
Early phase / not applicable (1)
Schizophrenia
NCT03019887 · Juntendo University
2011-04 – 2017-01 · Schizophrenia Relapse
What this study did

Competitive landscape

This mechanism is crowded: 24 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Schizophrenia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Quetiapine (Seroquel): this drugApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00305422: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)Reliable signal
NCT03172871: LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin
NCT00706654: Impending relapse by week 26: aripiprazole once-monthly 400 mg 7.12% vs oral aripiprazole 10-30 mg 7.76% (non-inferior); low-dose depot reference arm 21.80%
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT00712686: Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05).
Aripiprazole Lauroxil (Aristada Initio)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole Lauroxil (Aristada)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorReliable signal
NCT01469039: The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39)
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00212771: Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint
NCT00212784: Change in total PANSS score (52-week active-controlled trial): asenapine -21.0 vs olanzapine -27.5, difference P<0.0001. missed
Brexpiprazole (Rexulti)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT03198078: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014
NCT01396421: Change in PANSS total score at Week 6 vs placebo: brexpiprazole 2 mg treatment difference -8.72; 4 mg treatment difference -7.64 (both statistically significant).
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)Reliable signal
NCT01104766: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline to Week 6): Cariprazine 3.0 mg -20.2 Units on a Scale (Standard Error 1.5) | Cariprazine 6.0mg -23 Units on a Scale (Standard Error 1.5) vs Placebo -14.3 Units on a Scale (Standard Error 1.5) | Aripiprazole 10.0 mg -21.2 Units on a Scale (Standard Error 1.4)
NCT01104779: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline to Week 6): Cariprazine (3-6 mg/Day) -22.8 Units on a Scale (Standard Error 1.6) | Cariprazine (6-9 mg/Day) -25.9 Units on a Scale (Standard Error 1.7) vs Placebo -16 Units on a Scale (Standard Error 1.6)
ClozapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT03510325: Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed.
Haloperidol
ApprovedUS marketing discontinued
Small moleculeDopamine D2 receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00254202: Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2).
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptorPartial signal
NCT04959032: Study 304 (NCT04959032), time to relapse during double-blind phase: HR 0.37 (95% CI 0.22-0.65), 63% relapse-risk reduction vs placebo (p=0.0002); relapse rate 16.4% (18 relapses) lumateperone vs 38.6% (44 relapses) placebo
NCT02469155: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (6 weeks): Lumateperone 14 mg (ITI-007 20 mg Tosylate) -15 units on a scale (Standard Error 1.27) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) -14.6 units on a scale (Standard Error 1.23) vs Placebo -15.1 units on a scale (Standard Error 1.21) | Risperidone -20.5 units on a scale (Standard Error 1.33) missed
LurasidoneApprovedSmall moleculeDopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03465787: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority.
NCT00549718: Change in Total PANSS Score From Baseline to the End of the Double Blind Phase (6 weeks): Lurasidone 40mg -19.2 scores on a scale (95% CI -22.6 to -15.7) | Lurasidone 80mg -23.4 scores on a scale (95% CI -26.9 to -19.9) | Lurasidone 120mg -20.5 scores on a scale (95% CI -24 to -17.1) vs Placebo -17 scores on a scale (95% CI -20.5 to -13.6)
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Weltruza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist)Reliable signal
NCT05693935: Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 (Baseline, Week 8): Double-blind: TV-44749 318 mg -21.91 units on a scale (95% CI -25.13 to -18.7) | Double-blind: TV-44749 425 mg -23.44 units on a scale (95% CI -26.52 to -20.36) | Double-blind: TV-44749 531 mg -21.93 units on a scale (95% CI -25.01 to -18.85) vs Double-blind: Placebo -12.17 units on a scale (95% CI -15.34 to -8.99)
Olanzapine (Zyprexa Relprevv)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00088478: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each).
NCT00320489: Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision) (Baseline up to 104 weeks): Olanzapine Pamoate Depot 644.5 Days (IQR 162 to 740) vs Oral Olanzapine 677.5 Days (IQR 169.5 to 740) missed
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT03510325: Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 missed
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signal
NCT03187769: Percent change from baseline in body weight at Week 12: 4.91% ALKS 3831 vs 6.77% olanzapine; least-squares mean difference −1.87 percentage points (95% CI −3.33 to −0.41; p=0.012).
NCT02634346: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 (4 weeks): ALKS 3831 -23.9 units on a scale (Standard Error 1.28) vs Olanzapine -22.8 units on a scale (Standard Error 1.29) vs Placebo -17.5 units on a scale (Standard Error 1.32)
Paliperidone (Invega)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet graded
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 phase 3 result · pivotal pending
Paliperidone Palmitate (Erzofri)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Paliperidone Palmitate (Invega Sustenna)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT02431702: Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). missed
NCT00101634: PANSS total improved vs placebo in all three fixed-dose groups (p=0.02 for 25 and 50 mg equiv., p<0.001 for 100 mg equiv.).
Paliperidone Palmitate (Invega Trinza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178
NCT02713282: Symptomatic remission (Andreasen PANSS criteria) at LOCF/Month 12 endpoint: 172/303 patients, 56.8% (95% CI 51.0-62.4)
Perseris
ApprovedUS marketing discontinued
Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT02109562: Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162)
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT00640601: Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8)
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00253136: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly.
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03503318: Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181
Xanomeline / Trospium Chloride (Cobenfy)ApprovedSmall moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)Reliable signal
NCT04738123: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (From baseline up to Week 5): KarXT -20.6 Score on a scale (Standard Error 1.584) vs Placebo -12.2 Score on a scale (Standard Error 1.552)
NCT04659161: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (Baseline and Week 5): KarXT -21.2 score on a scale (Standard Deviation 1.652) vs Placebo -11.6 score on a scale (Standard Deviation 1.6)
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00403546: Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). missed
NCT00159770: Ziprasidone non-inferior to the olanzapine/risperidone/quetiapine group on total PANSS (margin 7 units; P<0.0001).
Cariprazine (Chengdu Kanghong)Phase 3Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (QLM1016)Phase 3Small moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signal
NCT04268303: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score (Baseline and 2 hours): 120 Micrograms — Baseline: 17.5 score on a scale (Standard Deviation 2.46); 2 Hours: -8.4 score on a scale (Standard Deviation 4.83) | 180 Micrograms — Baseline: 17.6 score on a scale (Standard Deviation 2.69); 2 Hours: -10.4 score on a scale (Standard Deviation 4.34) vs Placebo — Baseline: 17.6 score on a scale (Standard Deviation 2.26); 2 Hours: -4.7 score on a scale (Standard Deviation 4.69)
NCT05658510: Primary endpoint (SERENITY III Part 1, change from baseline in PEC total score at 2 hours), drug vs placebo: p=0.077, not statistically significant.
DireclidinePhase 3Small moleculeMuscarinic M4 receptorPartial signal
NCT05545111: PANSS total score at week 6: 7.5-point placebo-adjusted improvement (p=0.011, effect size 0.61) with 20 mg once daily; 18.2-point improvement from baseline
HS-10380Phase 3Small moleculeDopamine D2/D3 and serotonin 5-HT1A/5-HT2A receptors (multi-target)Partial signalNo reviewed efficacy summary in this indication
LB-102 (methylated Amisulpride)Phase 3Small moleculeDopamine D2/D3 receptor + 5-HT7 receptorReliable signal
NCT06179108: Change From Baseline to Week 4 in the PANSS Total Score (Baseline to Day 28 (4 weeks)): LB-102, 50 mg QD -14.28 score on a scale ± 1.097 vs LB-102, 75 mg QD -13.95 score on a scale ± 1.108 vs LB-102, 100 mg -16.08 score on a scale ± 1.906 vs Placebo Comparator -9.27 score on a scale ± 1.078; p=0.0009 (LB-102, 50 mg QD vs Placebo Comparator), p=0.0022 (LB-102, 75 mg QD vs Placebo Comparator), p=.0017 (LB-102, 100 mg vs Placebo Comparator)
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00628589: Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92)
Olanzapine / Samidorphan (Qilu)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist), Dopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
RoluperidonePhase 3Small moleculeSigma-2 receptor complex, Serotonin 5-HT2A receptor (antagonist / inverse agonist)Partial signal
NCT03397134: Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Roluperidone 32 mg — Baseline: 25.2 score on a scale (Standard Deviation 3.43); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.22); Change from Baseline to Week 4: -2.6 score on a scale (Standard Deviation 2.57); Change from Baseline to Week 8: -3.4 score on a scale (Standard Deviation 3.49); Change from Baseline to Week 12: -3.7 score on a scale (Standard Deviation 3.2) | Roluperidone 64 mg — Baseline: 25.3 score on a scale (Standard Deviation 3.26); Change from Baseline to Week 2: -1.7 score on a scale (Standard Deviation 2.47); Change from Baseline to Week 4: -2.8 score on a scale (Standard Deviation 2.92); Change from Baseline to Week 8: -3.8 score on a scale (Standard Deviation 3.32); Change from Baseline to Week 12: -4.5 score on a scale (Standard Deviation 3.85) vs Placebo — Baseline: 24.3 score on a scale (Standard Deviation 3.01); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.46); Change from Baseline to Week 4: -1.8 score on a scale (Standard Deviation 2.99); Change from Baseline to Week 8: -2.8 score on a scale (Standard Deviation 3.44); Change from Baseline to Week 12: -3.5 score on a scale (Standard Deviation 3.97) missed
UlotarontPhase 3Small moleculeTAAR1 (trace amine-associated receptor 1)Partial signal
NCT04092686: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): SEP-363856 75mg -16.4 score on a scale (Standard Error 1.49) | SEP-363856 100mg -18.1 score on a scale (Standard Error 1.5) vs Placebo -14.3 score on a scale (Standard Error 1.47) missed
NCT04072354: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): Adults: SEP-363856 50mg -16.9 score on a scale (Standard Error 1.57) | Adults: SEP-363856 75mg -19.6 score on a scale (Standard Error 1.56) vs Adults: Placebo -19.3 score on a scale (Standard Error 1.55) missed
ANAVEX3-71Phase 2Small moleculeSigma-1 receptor / muscarinic receptor (dual)Partial signal
NCT06245213: ANAVEX3-71-SZ-001 (NCT06245213) achieved its primary endpoint: ANAVEX3-71 was safe and well-tolerated, with no serious TEAEs and no severe TEAEs in either Part A or Part B.
Balipodect (TAK-063)Phase 2Small moleculePhosphodiesterase 10A (PDE10A)Partial signal
NCT02477020: Change From Baseline in the Positive and Negative Symptom Scale (PANSS) Total Score at Week 6 (Baseline and Week 6): TAK-063 -19.54 score on a scale (Standard Error 2.412) vs Placebo -14.08 score on a scale (Standard Error 2.474) missed
Betovumeline / Fesoterodine (ML-007C-MA)Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)Partial signal
NCT07038876: PANSS total score change at week 5 vs placebo (mITT): 210/3 mg BID, LS mean difference -4.5 points, Cohen's d 0.37, p=0.015, met. 330/6 mg QD, numerical improvement, not statistically significant (no figure given), missed.
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CPL500036Phase 2Small moleculePDE10AReliable signal
NCT05278156: Change from baseline in PANSS positive subscale at Day 28 (Week 4): 20 mg dose improved 3.7 points (p<0.001, Cohen's d=0.73); 40 mg dose improved 6.3 points (p<0.001, Cohen's d=1.38)
EmraclidinePhase 2Small moleculeMuscarinic M4 receptorPartial signal
NCT05227703: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Emraclidine 15mg QD -18.5 score on a scale (95% CI -22 to -15) | Emraclidine 30mg QD -14.2 score on a scale (95% CI -17.5 to -10.8) vs Placebo -16.1 score on a scale (95% CI -19.4 to -12.8) missed
GXV813Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
LY03020Phase 2Small molecule5-HT2C/TAAR1 receptorWeak signalNo reviewed efficacy summary in this indication
NBI-1117570Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2Small moleculeDendritic spine densitynot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)Phase 2Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
VV119Phase 2Small moleculeDopamine and serotonin receptors (multi-target antipsychotic)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine Long-Acting Injection (Mapi Pharma)Phase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
JX11502MAPhase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)Weak signal
NCT05233657: JX11502MA was generally well tolerated at a single dose of 0.25 to 3 mg. The most common treatment-emergent adverse events were somnolence (56.3%), nausea (21.9%), dizziness (18.8%), vomiting (18.8%) and hiccups (18.8%).
AticaprantPhase 1Small moleculeKappa-opioid receptor (inhibitor), Kappa opioid receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Brexpiprazole Long-Acting Injection (Kelun)Phase 1Small moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
HS-10509Phase 1Small molecule—Partial signalNo reviewed efficacy summary in this indication
LY03017Phase 1Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/5-HT2C, 5-HT2A/2C receptorWeak signalNo reviewed efficacy summary in this indication
NTX-253Phase 1Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Risperidone (QUAR)Phase 1Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
SEP-380135Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication
Paliperidone Palmitate (CSPC)
—(overall)
Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)Weak signal
NCT03892889: Percentage of Participants With Inpatient Psychiatric Hospitalization (Retrospective Period [Month -6 to Baseline (Day 1)] up to Prospective Period (Day 1 to Month 3)): Abilify MyCite® 0%
AVP-786DiscontinuedCombinationsigma-1/NMDAnot yet gradedNo reviewed efficacy summary in this indication
Clozapine (Fazaclo)DiscontinuedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Extended-Release Niacin (Niaspan)DiscontinuedSmall moleculeGPR109A (HCAR2)not yet gradedNo reviewed efficacy summary in this indication
NeloniclineDiscontinuedSmall moleculenicotinic acetylcholine receptor alpha7 (alpha7 nAChR)Partial signal
NCT01655680: MCCB neurocognitive composite, change from baseline to week 12 (primary analysis, ABT-126 50 mg vs placebo): +2.66 (±0.54) vs +2.46 (±0.56), P>0.05; 432 randomized. The UPSA-2ER key secondary also showed no significant difference. missed
Risperidone (Risvan)DiscontinuedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03160521: PANSS Total Score Mean Change From Baseline to Endpoint (Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)): Risperidone ISM 75 mg -24.6 units on a scale (Standard Error 1.51) | Risperidone ISM 100 mg -24.7 units on a scale (Standard Error 1.54) vs Placebo -11 units on a scale (Standard Error 1.56)
Rosiglitazone (Avandia)DiscontinuedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Quetiapine (Seroquel) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Early phase / not applicableBipolar DisorderRecruiting
Est. primary completion 2026-12-31 · NCT05480150 · CT.gov ↗
What to watch
2027 (1)
October 2027 (1)
Phase 4Parkinson's Disease PsychosisRecruiting
Est. primary completion 2027-10-24 · NCT04373317 · CT.gov ↗
What to watch
2028 (3)
June 2028 (2)
Phase 3Mild Traumatic Brain InjuryRecruiting
Est. primary completion 2028-06 · NCT06333990 · CT.gov ↗
What to watch
Phase 3Bipolar DepressionRecruiting
Est. primary completion 2028-06-30 · NCT05973786 · CT.gov ↗
What to watch
August 2028 (1)
Phase 3Treatment Resistant Depression (TRD)Not yet recruiting
Est. primary completion 2028-08-30 · NCT07760168 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 2/3Psychiatric Disorders, InsomniaRecruiting
Est. primary completion 2029-02-28 · NCT06062953 · CT.gov ↗
What to watch
2030 (1)
February 2030 (1)
Phase 4Bipolar DisorderActive not recruiting
Est. primary completion 2030-02-28 · NCT06433635 · CT.gov ↗
What to watch
2032 (1)
February 2032 (1)
Phase 2SchizophreniaNot yet recruiting
Est. primary completion 2032-02-01 · NCT07152184 · CT.gov ↗
What to watch

See the full readout calendar ↗